Healthcare Business
FDA Complete Response Letter Takes a Big Bite Out of Hope (SLXP, PGNX)
July 30, 2012 8:18 am
Last Updated: April 27, 2020 9:12 pm
Source: Jon Ogg
The CRL is now requesting additional clinical data. Salix and Progenics said that they intend to request an End-of-Review meeting with the Division of Gastroenterology and Inborn Errors Products to better understand the contents of the CRL.
Unfortunately the news is crushing. Progenix shares are down almost 50% at $5.45 in very active trading. The market cap prior to the drop was $365 million.
Salix was worth just over $3 billion and its shares are indicated down about 15% at $44.99 after a $53.19 close on Friday. So far we have seen Cantor Fitzgerald and Susquehanna downgrade Salix.
As is usual with Complete Response Letters, this means delays and higher costs of approval. It also is often is far worse than just that.
JON C. OGG
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Editors' Picks
